US/EU Agreement Will Reduce Global Import Testing Burden
Executive Summary
US drug makers will no longer have to retest batches exported to the EU under a mutual recognition agreement provision expected to take effect by July 2019. It's a landmark development in industry's quest to eliminate import testing, which it says wastes time and resources. But many nations around the world still require import testing – our interactive map shows which rules apply where.
You may also be interested in...
Batch Testing Of All Imported Drugs Floated At House Appropriations Hearing
While food oversight dominated lawmakers' attention, Republicans and Democrats were united on need to onshore more drug manufacturing to the US as FDA Commissioner Robert Califf testified about the agency’s fiscal year 2024 budget request.
European Enforcement Activity Picks Up After Medicines Agency's Relocation
With the European Medicines Agency's Amsterdam move completed and the US/EU inspections MRA guillotine stayed, lull in EU drug GMP noncompliance notices has ended.
US And EU Look To Expand Inspection Agreement
Product pre-approval inspections, vaccines and plasma-derived products are on the discussion agenda as the US-EU mutual recognition agreement takes full effect.